CXCL8 and ovarian cancer: Although CXCL8 or CXCR1/2 siRNAs have not yet been used clinically, a pre-clinical orthotopic ovarian cancer model has illustrated anti-tumor effects upon silencing of CXCL8 gene expression using liposome-encapsulated siRNA [181].